Hematologic Oncology

STAT3 inhibition using a novel compound restored sensitivity to TKIs in CML cells that had shown resistance independent of BCR-ABL1 kinase activity.

Continuous treatment with lenalidomide plus dexamethasone improved progression-free and overall survival in transplant-ineligible multiple myeloma patients.

A laboratory study found that natural killer cells could be multiplied from the blood of patients to fight off precursor B-lineage acute lymphoblastic leukemia.

Survivors of Hodgkin lymphoma may be at increased risk of diabetes if they were exposed to radiation to the para-aortic lymph nodes and spleen during treatment.

A new study confirms that patients with primary cutaneous diffuse large B-cell lymphoma who have a MYD88 mutation have a shorter disease-specific survival.

Phase II study results show that a new combination of drugs known as R2CHOP had promising efficacy in the treatment of relapsed diffuse large B-cell lymphoma.

The addition of gemtuzumab-ozogamicin to standard chemo improved event-free survival in children and young adults with newly diagnosed acute myeloid leukemia.

Treatment with bortezomib prior to autologous stem cell transplant resulted in superior outcomes in multiple myeloma patients with end-stage renal failure.

In a phase I trial, the oral AKT inhibitor afuresertib demonstrated single-agent activity against hematologic malignancies, specifically multiple myeloma.

Patients with pediatric BCR-ABL1-like acute lymphoblastic leukemia should be given risk-directed therapy based on minimal residual disease levels, according to a new study.

A combination of the CDK4 inhibitor palbociclib with ibrutinib in mantle cell lymphoma could potentially overcome the drug resistance that many patients face.

The FDA approved idelalisib (Zydelig) yesterday for the treatment of relapsed chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL), and small lymphocytic lymphoma (SLL).

Rapidly generated virus-specific T cells (VSTs) were safe and effective against five infections that commonly affect immunocompromised patients after marrow or stem cell transplantation, according to a new small study.

The FDA has granted breakthrough therapy designation to a novel treatment known as CTL019, a therapy intended for patients with relapsed/refractory acute lymphoblastic leukemia (ALL).

Is PCNSL resection safe? Evidence from clinical trials in which enrollment follows surgery-such as G-PCNSL-SG-1-is not valid proof of the safety of resection.

Relatively few patients with primary diffuse large B-cell lymphoma (PCNSL) will have tumors that are amenable to resection. In the absence of the highest quality data, at least it is good to know that in the modern era, patients with PCNSL are probably not harmed by judicious tumor resection.

For the practicing medical or neuro-oncologist, the treatment approach would currently not change, given that systemic therapy should be started as soon as the diagnosis of PCNSL is made and the patient is stable from a neurosurgical perspective. In most cases, one would not refer the patient back to the surgeon for additional debulking.

Prophylaxis with tacrolimus/sirolimus provided equivalent graft-vs-host disease-free survival in patients undergoing matched, related donor hematopoietic cell transplantation.

Lymphocyte infusions are extremely effective therapy in patients with chronic myeloid leukemia who relapse after allogeneic hematopoietic stem cell transplantation, and the timing of the infusion is relatively unimportant, according to a new study.

Researchers from Japan believe they have identified a novel staging system based on hemoglobin and plasmacytoma that may help to stratify patients with multiple myeloma who are treated with novel therapeutics.

Carfilzomib given at a higher dose as a slow intravenous infusion over 30 minutes resulted in a very high response rate in a heavily pretreated myeloma population.

Long-term outcomes of patients treated for pediatric acute lymphoblastic leukemia (ALL) with modern treatment protocols are good, with an overall low risk for serious long-term side effects.

The FDA has approved the drug belinostat to treat patients with relapsed or refractory peripheral T-cell lymphoma.

Measuring changes in levels of BCR-ABL in patients with chronic myeloid leukemia (CML) can help predict treatment outcomes and disease progression, according to a new study.

Researchers have identified Down syndrome as a risk factor for infection-related mortality among pediatric patients with acute lymphoblastic leukemia.

A comparison of melphalan, prednisone plus either thalidomide or lenalidomide found that patients assigned to lenalidomide had fewer grade 3 or higher toxicities and a better quality of life at the end of induction therapy.

This review will focus on newer FDA-approved targeted therapies associated with type II chemotherapy-related cardiac dysfunction, or generally reversible cardiotoxicity, and will provide the latest information on the incidence and clinical spectrum of cardiotoxicity associated with each therapy, modifiable risk factors where known, and the mechanisms of cardiotoxicity.

Treatment of relapsed or refractory multiple myeloma with the three-drug combination of panobinostat/bortezomib/dexamethasone resulted in a nearly 4-month improvement in progression-free survival compared to treatment with bortezomib/dexamethasone alone.

Ruxolitinib was significantly better than the best available therapy in a phase III, open-label trial of patients with polycythemia vera who were resistant to or intolerant of hydroxyurea.